Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 24:14:38.
doi: 10.1186/s13223-018-0262-9. eCollection 2018.

An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France

Patrick Blin  1   2 , Pascal Demoly  3 , Martine Drouet  4 , Bruno Falissard  5 , Séverine Lignot-Maleyran  1   2 , Hélène Maizi  1   2 , Simon Lorrain  1   2 , Régis Lassalle  1   2 , Cécile Droz-Perroteau  1   2 , Nicholas Moore  1   2   6 , Mathieu Molimard  6   7
Affiliations

An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France

Patrick Blin et al. Allergy Asthma Clin Immunol. .

Abstract

Background: Allergic rhinitis affects around one quarter of the Western European population. Prophylactic allergen immunotherapy may be useful to reduce the risk of acute symptomatic attacks (hayfever). A five-grass pollen extract sublingual immunotherapy (5GPE-SLIT) has been developed for the treatment of allergic rhinitis to grass pollen. The objective of this study was to describe real-world treatment patterns with 5GPE-SLIT in France with respect to the prescribing information.

Methods: This prospective cohort study was conducted by 90 community and hospital allergists. Adults and children (> 5 years old) starting a first treatment with 5GPE-SLIT prior to the 2015 pollen season were eligible. Data was collected at the inclusion visit and at the end of the pollen season. The primary outcome variable was compatibility of 5GPE-SLIT prescription with the prescribing information. This was determined with respect to four variables: (1) interval between 5GPE-SLIT initiation and onset of the pollen season ≥ 3 months, (2) age of patient ≥ 5 years, (3) intermittent symptoms or mild symptom severity (4) confirmatory diagnostic test. At study end, symptoms reported during the pollen season and any modifications to treatment or adverse events were documented.

Results: 280 adults and 203 children were enrolled. The prescribing information was respected for 82.5% of adults and 86.7% of children. A skin test was performed for all patients. 5GPE-SLIT was started 3-5 months before the pollen season for 85.3%. Treatment was discontinued before the start of the pollen season in 11.0% of patients overall, generally because of an adverse event (78.8% of discontinuations). The mean duration of treatment was 5.2 months in adults and 5.6 months in children. At the end of follow-up, symptoms during the pollen season were intermittent for 75.0% of adults and 85.7% of children, and severity was mild for 61.8 and 66.0% respectively. During 5GPE-SLIT, the following symptoms reported during the previous year were not reported again in > 50% of patients: nasal congestion, rhinorrhoea, repeated sneezing, conjunctivitis and nasal pruritus.

Conclusions: 5GPE-SLIT use was generally consistent with prescribing recommendations and was associated with an improvement of AR severity, with resolution of the principal AR symptoms in around half the patients treated.Trial registration EUPAS9358. Registered 13 May 2015. Not prospectively registered. http://www.encepp.eu/encepp/viewResource.htm?id=16229.

Keywords: Allergic rhinitis; France; Pollen season; Sublingual immunotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition
Fig. 2
Fig. 2
Time between treatment initiation and onset of pollen season
Fig. 3
Fig. 3
Comparison of prescription rates for acute and maintenance treatments for allergic rhinitis between the 2014 (grey square) and 2015 (black square) pollen seasons
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Update about Oralair® as a treatment for grass pollen allergic rhinitis.
    Klimek L, Brehler R, Mösges R, Demoly P, Mullol J, Wang DY, O'Hehir RE, Didier A, Kopp M, Bos C, Karagiannis E. Klimek L, et al. Hum Vaccin Immunother. 2022 Nov 30;18(5):2066424. doi: 10.1080/21645515.2022.2066424. Epub 2022 Jun 15. Hum Vaccin Immunother. 2022. PMID: 35704772 Free PMC article. Review.

References

    1. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372:456–463. doi: 10.1056/NEJMcp1412282. - DOI - PMC - PubMed
    1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x. - DOI - PubMed
    1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758–764. doi: 10.1183/09031936.04.00013904. - DOI - PubMed
    1. Klossek JM, Annesi-Maesano I, Pribil C, Didier A. INSTANT: national survey of allergic rhinitis in a French adult population based-sample. Presse Med. 2009;38:1220–1229. doi: 10.1016/j.lpm.2009.05.012. - DOI - PubMed
    1. Bhattacharyya N. Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy. 2012;26:120–122. doi: 10.2500/ajra.2012.26.3752. - DOI - PMC - PubMed

LinkOut - more resources